Beware of Stock Scams Tied to ‘Natural’ Products, FINRA Warns

Con artists behind these ‘pump and dump’ scams can sell off investors’ shares, leaving them with worthless stock

More On Legal & Compliance

from The Advisor's Professional Library
  • Risk-Based Oversight of Investment Advisors Even if the SEC had a larger budget and more resources, it is doubtful that the Commission would have the resources to regularly examine all RIAs. Therefore, the SEC is likely to continue relying on risk-based oversight to fulfill its mission of protecting investors.
  • Do’s and Don’ts of Advisory Contracts In preparation for a compliance exam, securities regulators typically will ask to see copies of an RIAs advisory agreements. An RIA must be able to produce requested contracts and the contracts must comply with applicable SEC or state rules.

The Financial Industry Regulatory Authority (FINRA) issued an Investor Alert Wednesday warning investors about stock scams related to nutraceutical companies that sell fortified foods, energy drinks and “natural” medicines.

The alert, Nutraceutical Stock Scams—Don't Supplement Your Portfolio With These Companies, warns investors that "con artists behind nutraceutical stock scams may try to lure in investors with optimistic and potentially false and misleading information that in turn creates unwarranted demand for shares of small, thinly traded companies that often have little or no history of financial success."

The con artists behind these “pump and dump” scams, the alert says, can then sell off their shares, leaving investors with worthless stock.

Like many investment scams, pitches for nutraceutical stocks may arrive in a variety of ways—from cold calls to e-mail, tweets, blogs or message board posts, the alert warns.

While some nutraceutical companies are legitimate, others could be bogus operations with the potential to harm unsuspecting investors.

The alert says one company claimed to have acquired rights to “all-natural” medicines that treat maladies ranging from the common cold to kidney disease.

The company claimed it had “the potential to capture 3% of the U.S. market within a three-year period” and “potentially generate $100,000,000 in revenues,” the alert says. FINRA’s alert says that investors who took a look at the company’s unaudited financials would have found a firm with almost no cash on hand and no track record of sales.

“While nutraceuticals claim to help people become healthy, investing in some of the companies associated with these products can make investors’ portfolios sick,” said Gerri Walsh, FINRA’s Vice President for Investor Education, in a statement. “The best way investors can inoculate themselves against investment scams is to ask and check. Find out whether the promoter is licensed using FINRA BrokerCheck, and check out the investment using the Securities and Exchange Commission's EDGAR database of company filings.”

Reprints Discuss this story
This is where the comments go.